

Tocilizumab Guided Questionnaire Myocardial Infarction/Acute Coronary Syndrome

AER.				Loc	case id.		
Site No:					Date of Birth (dd-MMM-yyyy):		
Patient ID/Initials:				Patie	ent Gender:	□М	F
Patient Weight	kg lb)		Pa	tient Height	cm	inch
Myocardial infarction and acute coronary syndrome have been observed in some patients treated with Tocilizumab. By filling in this questionnaire, you will help us to understand more fully the risk factors for this condition.							
Reporter Information							
Name of reporter completing this form: (if other than addressee, provide contact information below)							
Health Care Provider?							
Phone Number: Fax Number: Email Address:							
Reported Term							
Description of the	event						
Hospital Admission Yes (Admission Date MM/DD/YYYY): No							
(Discharge Date MM/DD/YYYY):							
Onset Date (MM/DD/YYYY)							
Stop Date (MM/DD/YYYY)							
Select all that apply:							
SERIOUSNESS CRITERIA CLASSIFICATION Death Date of Death (MM/DD/YYYY)							
Life-Threatening (use only if patient was at immediate risk of death due to event)							
☐Initial/Prolonged Hospitalization							
☐ Congenital Anomaly/Birth Defect ☐ Persistent or Significant Disability							
Medically Significant (important medical events that may jeopardize the patient and may require							
medical/surgical intervention to prevent the other outcomes)							

Version 1.0, Effective Date: 18-June-2012

Posi

☐ Non-Serious							
Related to Tocilizumab?	□Ye	es	☐ No				
Outcome of the event:	Persisting Resolved		proved known	☐Recovered with sequelae ☐Worsened ☐Death			
Drug therapy details -	Tocilizumab						
Indication:							
Start Date (MM/DD/YYYY)					_		
Starting Dose		mg.	/kg	Total monthly dose (mg)			
Route							
Frequency	☐ Monthly	y		Other, please specify:			
	Dat (MM/DD/		Dose	Action Taken in response to AE?	\exists		
History of 4 most recent Infusions prior to Adverse Event (AE)				□ Dose maintained □ Dose decreased □ Dose interrupted □ Dose increased □ Dose discontinued □ Dose maintained □ Dose decreased □ Dose interrupted □ Dose increased □ Dose discontinued □ Dose maintained □ Dose maintained □ Dose interrupted □ Dose discontinued □ Dose discontinued □ Dose maintained □ Dose decreased □ Dose interrupted □ Dose interrupted □ Dose interrupted □ Dose increased □ Dose discontinued			
Treatment for the ever	nt						
What treatment was initiat	ed for the eve	nt? (inclu	ıding any pre	e-hospitalization treatment)			
Treatment		Dosing Regimen		Dates of Therapy (MM/DD/YYYY to MM/DD/YYYY)			

Please attach all laboratory results (fasting cholesterol panel, cardiac enzymes, platelets) and imaging tests. Please provide SI (International System of Units) if available. Otherwise, as reported. Labs Attached									
Please indicate if any of the following tests have been performed, and the result:									
	Baseline Value (Prior to TCZ Use)	Date of Baseline Test (MM/DD/YYY	t (MM/DD/	Date of Test (MM/DD/YYYY)		Reference Range (If Applicable)	Pending?		
Coronary Angiography						,,,,,,	Yes		
CT Scan							Yes		
Echocardiography							Yes		
Electrocardiogram							Yes		
Stress Test							Yes		
PTCA							Yes		
CABG							Yes		
Stent							Yes		
Other Please specify:							Yes		
Risk Factors									
Please indicate if the following conditions are either part of the patient's medical history or are still active conditions.									
Family history of ca disease Specify:	∏History	History Concurrent			□Not present				
Coronary Artery Dis Specify:	☐History	/ 🗆	Concurrent		□Not present				
Previous Myocardia	□History	/ 🗆	Concurrent		☐Not present				
Cardiac Valve Dise	☐History	/ 🔲 🗆	Concurrent		☐Not present				
Diabetes Mellitus	□History	/ 🔲	Concurrent		☐Not present				
Hypertension	□History	y Concurrent		☐Not present					
Hypercholesterolen	☐History	/ 🔲 🗆	Concurrent		☐Not present				
Smoking		History	/ 🔲 🗆	Concurrent		☐Not present			
Obesity		☐History	/ DO	Concurrent		□Not present			
Other		History	/ 🗆	Concurre	ent	☐Not prese	nt		
Please specify:									

Past/Concomitant M	edications				
	ttached				
		Dose	Route	Frequency	Past, Concomitant, or N/A
Methotrexate	Yes No				□Past □Concomitant □N/A
Other DMARDs Specify:	☐ Yes ☐ No				□Past □Concomitant □N/A
Biologic DMARDs Specify:	☐ Yes ☐ No				□Past □Concomitant □N/A
Corticosteroids Specify:	☐ Yes ☐ No				□Past □Concomitant □N/A
Lipid lowering Medications Specify:	☐ Yes ☐ No				☐Past ☐Concomitant ☐N/A
Antihypertensive medication Specify:	☐ Yes ☐ No				□Past □Concomitant □N/A
Aspirin/ anti-platelet Specify:	☐ Yes ☐ No				□Past □Concomitant □N/A
Other Please specify:	☐ Yes ☐ No				□Past □Concomitant □N/A
Please provide any there have been ar					Iverse Event. Please indicate if ort.
Γhank you for comբ	leting this	s form.			
Completed by:					
Name: Position:					

Signature:	Date:	
E-mail:		

.....